Scotiabank lowered the firm’s price target on Keros Therapeutics (KROS) to $26 from $41 and keeps an Outperform rating on the shares. The firm is updating its price targets on biotechnology stocks following Q1 results, the analyst tells investors. The firm sees limited value-driving catalysts for the stock in the near-term.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics CEO to Speak at Healthcare Conference
- Keros Therapeutics price target lowered to $25 from $40 at H.C. Wainwright
- Keros Therapeutics: Buy Rating Affirmed Amid Promising Trial Data and Strategic Initiatives
- Keros Therapeutics Reports Strong Q1 2025 Results
- Keros Therapeutics: Promising Developments Amidst Uncertainties Lead to Hold Rating